{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:36:39Z","timestamp":1762454199955,"version":"build-2065373602"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>We identified an effective chemotherapy regimen in patients refractory to standard chemotherapy. We included patients with unresectable colorectal liver metastases who underwent hepatic artery infusion chemotherapy and systemic chemotherapy between January 2015 and December 2022. This study was a retrospective analysis conducted at a single center. The patients received either biweekly oxaliplatin and 5-fluorouracil through hepatic artery infusion chemotherapy as well as bevacizumab and leucovorin injected intravenously (HAIC-FOLFOX-B) or biweekly irinotecan and 5-fluorouracil by hepatic artery infusion chemotherapy and bevacizumab and leucovorin injected intravenously (HAIC-FOLFIRI-B). Of the 42 patients, 20 underwent HAIC-FOLFOX-B while 22 underwent HAIC-FOLFIRI-B treatment with response rates of 25% and 4.5%, respectively. The median overall survival and progression-free survival were 12.9 and 4.7 months and 17.4 and 7.7 months in patients undergoing HAIC-FOLFOX-B and HAIC-FOLFIRI-B, respectively. The overall incidence of grade 3\/4 toxicity was 23.8%. However, no treatment-related deaths occurred. Functional catheter-associated problems occurred in 9.5% of the patients. Hepatic arterial occlusion occurred in three patients (7.1%); catheter-associated infection occurred in one (2.4%) patient. However, these occurrences were not life-threatening complications. HAIC-FOLFOX-B and HAIC-FOLFIRI-B might improve survival in patients with unresectable colorectal liver metastases and in those who underwent both systemic oxaliplatin-based and irinotecan-based chemotherapies and were refractory to them. HAIC FOLFOX-B and FOLFIRI-B regimens might be effective therapeutic options in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0336230","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:31:51Z","timestamp":1762453911000},"page":"e0336230","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7081-7679","authenticated-orcid":true,"given":"Masatsugu","family":"Ishii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-9508","authenticated-orcid":true,"given":"Osamu","family":"Itano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Itano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"pone.0336230.ref001","article-title":"Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment","author":"E Van Cutsem","year":"2010","journal-title":"Ann Oncol"},{"issue":"16","key":"pone.0336230.ref002","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer","volume":"18","author":"A de Gramont","year":"2000","journal-title":"JCO"},{"issue":"9209","key":"pone.0336230.ref003","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"JY Douillard","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"pone.0336230.ref004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"RM Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0336230.ref005","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"LB Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0336230.ref006","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"C Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"31","key":"pone.0336230.ref007","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"J-Y Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"pone.0336230.ref008","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"E Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0336230.ref009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","article-title":"First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer","volume":"138","author":"C-H K\u00f6hne","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"pone.0336230.ref010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"C Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9863","key":"pone.0336230.ref011","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"A Grothey","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"pone.0336230.ref012","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"T Yoshino","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"11","key":"pone.0336230.ref013","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1990.8.11.1885","article-title":"A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver","volume":"8","author":"LD Wagman","year":"1990","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0336230.ref014","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1992.10.7.1112","article-title":"Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial","volume":"10","author":"P Rougier","year":"1992","journal-title":"J Clin Oncol"},{"issue":"8932","key":"pone.0336230.ref015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(94)90750-1","article-title":"Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases","volume":"344","author":"TG Allen-Mersh","year":"1994","journal-title":"Lancet"},{"issue":"9","key":"pone.0336230.ref016","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)","volume":"24","author":"NE Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"issue":"35","key":"pone.0336230.ref017","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1200\/JCO.2007.12.1764","article-title":"Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?","volume":"25","author":"S Mocellin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0336230.ref018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-012-2014-8","article-title":"Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver","volume":"71","author":"AM Tsimberidou","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"pone.0336230.ref019","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10637-015-0251-5","article-title":"Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver","volume":"33","author":"R Said","year":"2015","journal-title":"Invest New Drugs"},{"issue":"6","key":"pone.0336230.ref020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)","volume":"18","author":"JP Vandenbroucke","year":"2007","journal-title":"Epidemiology"},{"issue":"11","key":"pone.0336230.ref021","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s11604-014-0361-6","article-title":"Intermittent transcatheter therapy through a new indwelling catheter system for patients with hepatocellular carcinoma","volume":"32","author":"O Itano","year":"2014","journal-title":"Jpn J Radiol"},{"issue":"3","key":"pone.0336230.ref022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11604-021-01202-9","article-title":"Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors","volume":"40","author":"H Iwamoto","year":"2022","journal-title":"Jpn J Radiol"},{"issue":"4","key":"pone.0336230.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266707","article-title":"Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma","volume":"17","author":"M Ishii","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"pone.0336230.ref024","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000523703","article-title":"Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study","volume":"100","author":"M Ishii","year":"2022","journal-title":"Oncology"},{"issue":"3","key":"pone.0336230.ref025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ags3.12071","article-title":"Recent advances in treatment for colorectal liver metastasis","volume":"2","author":"E Oki","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"issue":"2","key":"pone.0336230.ref026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"C Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"10","key":"pone.0336230.ref027","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jvir.2007.05.011","article-title":"Clinical utility of coaxial reservoir system for hepatic arterial infusion chemotherapy","volume":"18","author":"A Hamada","year":"2007","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"pone.0336230.ref028","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1477-7819-11-203","article-title":"Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report)","volume":"11","author":"K Sawai","year":"2013","journal-title":"World J Surg Oncol"},{"key":"pone.0336230.ref029","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12957-015-0704-5","article-title":"Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer","volume":"13","author":"T Goi","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"1","key":"pone.0336230.ref030","article-title":"Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era","volume":"21","author":"YJ Ko","year":"2014","journal-title":"Curr Oncol"},{"issue":"6","key":"pone.0336230.ref031","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/annonc\/mdg247","article-title":"Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer","volume":"14","author":"D Fallik","year":"2003","journal-title":"Annals of Oncology"},{"key":"pone.0336230.ref032","first-page":"1837","article-title":"Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases","volume":"23","author":"R Mancini","year":"2003","journal-title":"Anticancer Res"},{"issue":"22","key":"pone.0336230.ref033","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer","volume":"23","author":"M Ducreux","year":"2005","journal-title":"JCO"},{"key":"pone.0336230.ref034","first-page":"707","article-title":"Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study","volume":"20","author":"G Fiorentini","year":"2006","journal-title":"In Vivo"},{"issue":"85","key":"pone.0336230.ref035","first-page":"1419","article-title":"Hepatic arterial infusion combined with oral UFT\/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer","volume":"55","author":"S Tsutsumi","year":"2008","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"pone.0336230.ref036","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000183732","article-title":"Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer","volume":"55","author":"E Idelevich","year":"2009","journal-title":"Chemotherapy"},{"issue":"21","key":"pone.0336230.ref037","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"NE Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0336230.ref038","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes","volume":"261","author":"MI D\u02bcAngelica","year":"2015","journal-title":"Ann Surg"},{"issue":"2","key":"pone.0336230.ref039","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"FA L\u00e9vi","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"pone.0336230.ref040","first-page":"308","article-title":"Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study","volume":"16","author":"A Lim","year":"2017","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"pone.0336230.ref041","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential","volume":"117","author":"LM Pak","year":"2018","journal-title":"J Surg Oncol"},{"issue":"1","key":"pone.0336230.ref042","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/s10434-016-5418-6","article-title":"Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study","volume":"24","author":"M Dhir","year":"2017","journal-title":"Ann Surg Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:31:56Z","timestamp":1762453916000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336230"}},"subtitle":[],"editor":[{"given":"Keun-Yeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336230","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}